Evidence map›Paper›PMID 31349875›Full record

ArticleActa neuropathologica communications2019

Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.

Kanish Mirchia, Matija Snuderl, Kristyn Galbraith, Kimmo J Hatanpaa, Jamie M Walker, Timothy E Richardson

Abstract readLetter
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Chromosomal instability in adult-type diffuse gliomas.Acta neuropathologica communications · 2022
    Review
  9. Article
  10. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.Laboratory investigation; a journal of technical methods and pathology · 2022
    Review
  11. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  12. Article
  13. Open life sciences · 2021
    Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kanish MirchiaDepartment of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.
Matija SnuderlDepartment of Pathology, New York University Langone Health, New York City, NY, 10016, USA.
Kristyn GalbraithDepartment of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.
Kimmo J HatanpaaDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Jamie M WalkerDepartment of Pathology, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
Timothy E RichardsonDepartment of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA. RichaTim@Upstate.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAstrocytomaBrain NeoplasmsDNA Copy Number VariationsFemaleHumansIsocitrate DehydrogenaseMaleMutationNeoplasm GradingPrognosisSurvival RateIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseAstrocytomaCNACNVCopy number alterationsCopy number variationGBMGlioblastomaGliomaIDH mutationTCGA

Identifiers

PMID31349875
PMCPMC6660955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.